PT - JOURNAL ARTICLE AU - Knabl, Ludwig AU - Lee, Hye Kyung AU - Walter, Mary AU - Furth, Priscilla A. AU - Hennighausen, Lothar TI - Omicron BA.1 and BA.2 immune response in naïve and prior infected persons AID - 10.1101/2022.04.07.22273565 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.07.22273565 4099 - http://medrxiv.org/content/early/2022/04/10/2022.04.07.22273565.short 4100 - http://medrxiv.org/content/early/2022/04/10/2022.04.07.22273565.full AB - The highly transmissible SARS-CoV-2 Omicron (B.1.1.529) variant has replaced previous variants and is less susceptible to neutralizing antibodies elicited by vaccination or infection1–3. Currently, BA.2 is the dominant omicron sublineage4. Vaccinated individuals with BA.1 infection develop measurable neutralizing antibody titers against BA.1 and BA.25. The ability of BA.2 infection to induce neutralizing antibodies in unvaccinated individuals, either without or with previous SARS-CoV-2 infection, is pending definition.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Intramural Research Program (IRP) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved (EK Nr: 1064/2021) by the Institutional Review Board (IRB) of the Office of Research Oversight/Regulatory Affairs, Medical University of Innsbruck, Austria, which is responsible for all human research studies conducted in the State of Tyrol (Austria). Participant information was coded and anonymized.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe don't have data needed to upload.